Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroinflammation, Pain, and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPM2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Target | TRPM2 Lentivirus / Stable Cell Line Premade. Ideal for complex ion channel conformation preservation. Sequence Verified. | View TRPM2 Products |
| Purified Protein (NUDT9-H Domain) | TRPM2 NUDT9-H Domain Protein (>95% purity, E. coli expressed). For ADPR-binding and enzymatic assays. | View TRPM2 Products |
| Gene Delivery | TRPM2 Promise-ORF (Full-length ORF for stable cell lines). | View TRPM2 Products |
| Benchmark Ab | Anti-TRPM2 Control Antibody (Recombinant positive control for western blot and FACS). | View TRPM2 Products |
| Validator | TRPM2 siRNA Set (3 unique targets, >70% knockdown). For specificity checks and genetic validation. | View TRPM2 Products |
| Related Target A | PARP1 (Generates ADPR, the primary endogenous activator of TRPM2). | View PARP1 Products |
| Related Target B | CD38 (Involved in NAD+ metabolism and cADPR production linked to TRPM2 activation). | View CD38 Products |
| Related Target C | TRPM4 (Cardiac safety counter-screening; calcium-impermeable TRP family member). | View TRPM4 Products |
| Related Target D | NLRP3 (Downstream signal validation; ROS-activated inflammasome partner). | View NLRP3 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multipass Membrane Conformation | Lentivirus-mediated stable cell expression preserves native ion channel structures for Calcium Flux assays. |
| ADPR-Binding vs Channel Blocking Selectivity | Isolated NUDT9-H Domain Protein (>95% purity) for enzymatic/binding assays distinct from whole-cell electrophysiology. |
| TRP Family Cross-Reactivity / Selectivity | Sequence verified strict controls; TRPM4 protein available for counter-screening to exclude TRPM2 cross-reactivity. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks and genetic validation. |
| Oxidative Stress Model Compatibility | Endotoxin-controlled reagents (<1 EU/μg) prevent innate immune activation confounding ROS-sensitive TRPM2 assays. |
Live TRPM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPM2 therapeutics is intensifying, with major players shifting focus from non-selective ion channel blockers to highly specific targeted inhibitors. First-generation therapies are advancing toward clinical trials for ischemia-reperfusion injury, stroke, and neurodegenerative diseases. The next wave of R&D targets neuroinflammation, neuropathic pain, Alzheimer's and Parkinson's disease through precise modulation of the TRPM2 channel pore and its intracellular NUDT9-H domain. Combination therapies with anti-inflammatory agents and blood-brain barrier penetrant formulations are key emerging trends.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Academic/Biotech, Janssen, Hydra Biosciences | Stroke, Neuropathic Pain, Ischemia-Reperfusion Injury | Calcium Flux Assay (Need stable TRPM2 cell lines via lentivirus) |
| NUDT9-H Domain Inhibitor | Academic Consortia | Diabetes, Metabolic Syndrome | ADPR Binding Assay (Need purified NUDT9-H domain protein) |
| Monoclonal Antibody | Early Stage Innovators | Inflammation | Binding Validation (Need native HEK293 expression) |
| Neuroprotective Agent | Biotech Startups | Alzheimer's, Parkinson's Disease | Blood-Brain Barrier Penetration Model (Need high-purity proteins for binding kinetics) |
| Anti-Inflammatory Compound | Immunology Focused Firms | NLRP3 Inflammasome Diseases | TRPM2-NLRP3 Axis Validation (Need siRNA for specificity confirmation) |
Genomic Variants & Functional Insights
TRPM2 carries clinically relevant single nucleotide variants: dbSNP rs45625933, rs45544142, and rs45485992 (source: UniProt O94759). These variants may influence channel function and drug response, underscoring the need for sequence-verified reagents in preclinical assays.